SHANDONG XINHUA (00719) announced that it has recently obtained the Drug Registration Certificate for Alendronate Sodium Oral Solution from the National Medical Products Administration (NMPA). The oral solution is indicated for the treatment of osteoporosis in postmenopausal women to prevent hip and vertebral fractures (vertebral compression fractures), as well as to increase bone mass in men with osteoporosis. According to relevant statistics, alendronate sodium generated sales of RMB 720 million in 2024 across three major channels in China, including public hospitals, primary healthcare institutions, and retail pharmacies.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.